Orthovita launches Vitagel
This article was originally published in The Gray Sheet
Executive Summary
Firm's 40-person direct sales team targets more than 500 hospitals in the U.S. following launch of the hemostatic spray, indicated to control bleeding in cardiovascular, spinal, orthopedic and general surgery procedures. Orthovita's marketing partner Angiotech expects to transfer Vitagel production capabilities to the former firm's Malvern, Penn. facility by Q3 2005. The device, originally known as CoStasis and marketed by Tyco/U.S. Surgical, received PMA approval in 2000 (1"The Gray Sheet" June 28, 2004, p. 30)...